MedTrace Logo

Study of IBI318 in Participants With Advanced Malignancies

NCT03875157 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2023-02-27

No results posted yet for this study

Summary

An open label, multicenter, phase Ia/Ib study to evaluate the safety, tolerability, and initial efficacy of IBI318 in the treatment of patients with advanced malignancies.

Conditions

  • Advanced Malignancy

Interventions

BIOLOGICAL

IBI318

0.3 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

1 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

3 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

10 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

30 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

100 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

300 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

600 mg intravenous infusion, C1D1 and afterwards Q2W

BIOLOGICAL

IBI318

Intravenous infusion, C1D1 and afterwards Q3W

BIOLOGICAL

IBI318

Intravenous infusion, C1D1 and afterwards Q3W

BIOLOGICAL

IBI318

Intravenous infusion Q3W

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-19
Primary Completion
2023-02-16
Completion
2023-02-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875157 on ClinicalTrials.gov